ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Tenaya Therapeutics raises $92 million in series B financing

by Ryan Cross
October 3, 2019 | APPEARED IN VOLUME 97, ISSUE 39

 

Tenaya Therapeutics, a start-up with six academic cofounders from the Gladstone Institutes and the University of Texas Southwestern, has raised $92 million in series B financing. Tenaya is developing gene therapies for rare genetic heart conditions, as well as a gene therapy that uses a cocktail of transcription factors to convert fibroblasts into heart muscle cells after a heart attack. It is also using patient-derived cells to screen for small molecules that can treat genetic heart diseases.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment